Macro Crown Biopharmaceutical

Macro Crown Biopharmaceutical is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the discovery and development of next-generation antibody therapeutics for oncology and autoimmune diseases. The company leverages its proprietary M-Crown platform to engineer multi-specific antibodies designed to overcome resistance to current checkpoint inhibitors. Its lead programs focus on dual-targeting immune checkpoints to enhance T-cell activation within the tumor microenvironment. Macro Crown aims to provide more effective and safer treatment options for patients with refractory solid tumors through innovative protein engineering.